Results 71 to 80 of about 1,128 (134)
Vaccination against pneumococcus in West Africa: perspectives and prospects
Eric S Donkor,1 Nicholas TKD Dayie,1,2 Ebenezer V Badoe3 1Department of Microbiology, University of Ghana Medical School, Accra, Ghana; 2Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen ...
Donkor ES, Dayie NT, Badoe EV
doaj
Update on the success of the pneumococcal conjugate vaccine
Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Canada and elsewhere, routine infant vaccination has led to near eradication of invasive pneumococcal disease caused by vaccine serotype strains in both children and adults.
openaire +2 more sources
Experience with pneumococcal conjugate vaccine in Norway
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly.
openaire +2 more sources
Invasive pneumococcal disease (IPD) results from the dissemination of Streptococcus pneumoniae to normally sterile anatomical sites such as the bloodstream or cerebrospinal fluid. One of the primary roles of pneumococcal conjugate vaccines (PCVs) used in
Endre Csaba Pál +7 more
doaj +1 more source
Pneumococcal conjugate vaccines in different settings [PDF]
openaire +2 more sources
Pneumococcal conjugate vaccine and pneumococcal common protein vaccines
Keith P. Klugman +4 more
openaire +1 more source
III. Characteristics and Differences in Pneumococcal Vaccines; 2. Pneumococcal Conjugate Vaccine
openaire +3 more sources
Assessing the Impact of Pneumococcal Conjugate Vaccines
openaire +2 more sources
Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine
openaire +1 more source

